My clients turn to me as a trusted advisor in critical financing and corporate transactions.

Passions

Tennis

Golf

Cycling

Experience

Redx Pharma to Merge With Jounce Therapeutics

March 6, 2023

Cooley advised Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.

Related contacts

Michal Berkner
Partner, London
Claire Keast-Butler
Partner, London
Russell Anderson
Associate, London
Rita Sobral
Associate, London
Natasha Kaye
Partner, London
Nicola Squire
Partner, London
Aaron Pomeroy
Partner, Colorado
Megan Browdie
Partner, Washington DC
Caroline Hobson
Partner, London
Paula Holland
Partner, London
David Wilson
Partner, London
Josh Kaufman
Partner, New York
Laurence Harris
Partner, London
Chris Stack
Partner, London
Jeff Goldman
Special Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington DC
Stacey A. Bradford
Special Counsel, Washington DC
Charlotte Irvine
Associate, London
Vlad Herta
Associate, London
Bethan Chalmers
Associate, London
Dov Fiskus
Associate, New York
Amanda Griggs
Associate, New York
Anna Caro
Associate, London
Rick Jantz
Associate, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego

Silence Therapeutics – $56.5 Million Registered Direct Offering

September 7, 2022

Cooley advised Silence Therapeutics in a $56.5 million registered direct offering of 5,950,000 American Depositary Shares (ADS), each representing three ordinary shares, at a price of $9.50 per ADS. Silence is a biotechnology company focused on discovering and developing molecules incorporating novel short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Partners Josh Kaufman, Div Gupta, Nicolas H.R. Dumont and Claire Keast-Butler led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Div Gupta
Partner, New York
Nicolas H.R. Dumont
Partner, New York
Claire Keast-Butler
Partner, London
Sam Meiklejohn
Associate, London
Giovanna Robledo
Associate, New York

Related Practices & Industries

Arbor Realty Trust – $123 Million Offering

July 8, 2022

Cooley advised the underwriters on Arbor Realty Trust’s $123.9 million offering of 7,475,000 shares at $16.57 per share. Arbor Realty Trust is a national direct lender that provides debt capital for the multifamily loan and commercial real estate industries. Partners Daniel Goldberg, Josh Kaufman and Courtney M.W. Tygesson led the Cooley team.

Related contacts

Daniel I. Goldberg
Partner, New York
Josh Kaufman
Partner, New York
Courtney M.W. Tygesson
Partner, Chicago
Amiti C. Rothstein
Associate, New York
Olivia Creser
Associate, New York

Related Practices & Industries

IN8bio – $40 Million IPO

August 4, 2021

Cooley advised IN8Bio on its $40 million initial public offering of 4,000,000 shares of common stock. IN8Bio, whose securities now trade on the Nasdaq Global Market under the symbol INAB, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell therapies. Partners Josh Kaufman, Jaime Chase and Josh Rottner led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Jaime L. Chase
Partner, Washington DC
Joshua Rottner
Partner, Boston

Related Practices & Industries

Sprinklr – $293 Million IPO

June 26, 2021

Cooley advised Sprinklr on its $292.6 million initial public offering of 18,287,500 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Sprinklr, whose securities now trade on the New York Stock Exchange under the symbol CXM, is the unified customer experience management platform for modern enterprises. Partners Nicole Brookshire, Josh Kaufman and Jaime Chase led the Cooley team.

Related contacts

Josh Kaufman
Partner, New York
Jaime L. Chase
Partner, Washington DC
Charles York
Associate, New York

Related Practices & Industries

View more